Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes

Trial Profile

A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2019 Results of sub-group analysis of two categories [patients aged between 65 and 74 years (low age group) and patients aged 75 years and over (high age group)] assessing efficacy and tolerability of Fentyl sublingual tablets in cancer pain patients, published in the Drugs in R and D.
    • 31 Jul 2017 New trial record
    • 25 Jul 2017 Results of subgroup (age more than or equal to 65 years and less than 65 years) analysis published in the Drugs in R and D
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top